Martin E. Cooper. Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837. // Obesity Reviews. – 2026. – DOI: 10.1111/obr.70166. – URL: https://onlinelibrary.wiley.com/doi/10.1111/obr.70166?af=R
Martin E. Cooper (2026). Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837. Obesity Reviews. https://doi.org/10.1111/obr.70166
Martin E. Cooper. “Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837.” Obesity Reviews, 2026. doi:10.1111/obr.70166.
@article{Cooper2026,
title = {Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837},
author = {Cooper, Martin E.},
journal = {Obesity Reviews},
year = {2026},
doi = {10.1111/obr.70166},
url = {https://onlinelibrary.wiley.com/doi/10.1111/obr.70166?af=R}
}
Abstract Aim Discretionary foods and beverages contribute to poor diet quality and chronic disease. In Australia, intake exceeds dietary guideline recommendations and is unlikely to improve without substantial intervention. We examined...
ABSTRACT Background Ultra‐processed foods (UPFs) are a leading contributor to diet‐related chronic disease and socio‐ecological harm. Despite increasing recognition of these impacts, regulatory responses remain fragmented, focused on...